The Efficacy of Omega-3 Supplement on Prevention of Retinopathy of Prematurity in Premature Infants: A Randomized Double-blinded Controlled trial

Author(s): Nasrin Khalesi, Arash Bordbar, Nastaran Khosravi*, Morteza Kabirian, Alireza Karimi.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 17 , 2018

Abstract:

Background: The present study aimed to assess the efficacy of omega-3 in treating ROP in premature infants.

Methods: This randomized double-blinded controlled trial was performed on 160 premature infants with gestational age lower than 32 weeks and birth weight < 1500 grams who were at risk of ROP development (Tehran, Iran-2013). Children were randomly assigned to two groups. The intervention group received 300 mg omega-3 daily and the control group received sterile water as the placebo. The severity of ROP was defined according to the International Classification of ROP.

Results: The frequency of ROP was 7.5% in the group received omega-3 and 20.0% in the placebo group with a significant difference (p = 0.021). Regarding the severity of ROP in the intervention group, ROP grade I was found in two patients and ROP grade II in four patients; while ROP grade I, II, and III were revealed in 6, 6, and 4 patients in placebo group indicating a significant difference between the two groups (p = 0.001). Using the multivariate logistic regression modeling with the presence of gender, gestational age, and birth weight, the use of omega-3 was associated with reduced risk for ROP (p = 0.045).

Conclusion: The use of omega-3 supplement can be an appropriate treatment option for the treatment of ROP in premature infants.

Keywords: Retinopathy, gestational age, placebo, low birth weight, prematurity, omega-3.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 17
Year: 2018
Page: [1845 - 1848]
Pages: 4
DOI: 10.2174/1381612824666180601094849
Price: $58

Article Metrics

PDF: 18
HTML: 1